Trial Profile
Study on the utility, and palatability of meal in novel SGLT-2 inhibitor ipragliflozin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
- 17 Jul 2014 New trial record